Factory CRO announced that it has acquired MileStone Research Organization. The financial details of the deal were not disclosed.
“The merger with MileStone is an important step in building Factory’s operational strength and service range in North America,” Dirk Meijer, Factory CRO’s CEO, said. “MileStone is an excellent fit therapeutically, as well as culturally, and complements our existing U.S. operations in Austin, Texas, and Princeton, N.J. Milestone’s extensive expertise in orthopedics, neurological and IVD clinical trials, as well as their reimbursement and site management service offerings, is a fantastic value-add for all our clients.”
Factory CRO works on safety, efficacy and clinical economics studies and quality-of-life and post-marketing studies for medical device, IVD and drug-device products. The company has performed more than 450 projects in Class II and III medical devices globally.
“The combination of Factory and MileStone is good for everyone,” said Kevin Liang, founder of MileStone Research Organization. “Our specialization in clinical and regulatory affairs, as well as reimbursement for innovative technologies, aligns us perfectly with Factory. Factory’s full-service clinical offerings and extensive knowledge of the European regulatory environment will greatly expand our reach. The mutual commitment of both organizations to provide world-class solutions and superior client support will continue to motivate the company’s growth moving forward.”
